Time to scale new heights or crash into the sea

As the pharma and biotech industry prepare to gather for the annual JP Morgan Healthcare Conference in San Francisco next week, all eyes are on potential deal announcements and strategic collaborations.

Among the hottest emerging areas of interest?

A new wave of engineered agents is emerging, which may potentially transform cancer treatment by addressing some of the weaknesses inherent with existing therapies.

If companies can solve some fundamental challenges – after all, no approach is without them – then this emerging class of agents could turn out to be an unexpected winner, winner chicken dinner.

It also has the propensity for high risk/high reward built in, which means either scaling new heights and blockbuster status or crashing into the sea below might be the spectacular end result either way…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by